Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma (iINHALE 9)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00523042|
Recruitment Status : Terminated (See termination reason in detailed description)
First Posted : August 30, 2007
Last Update Posted : March 1, 2017
This trial is conducted in Europe, Asia, Oceania and the United States of America (USA).
This is a one-year clinical trial to compare the safety of inhaled preprandial human insulin to subcutaneous insulin aspart in subjects with type 1 or 2 diabetes and asthma.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Asthma||Drug: insulin aspart Drug: inhaled human insulin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Inhaled Preprandial Human Insulin With the AERx® iMS Versus Subcutaneous Injected Insulin Aspart in Subjects With Diabetes and Asthma: A 52-week, Open-label, Multinational, Randomised, Parallel Trial to Investigate Long-term Safety|
|Actual Study Start Date :||August 30, 2007|
|Primary Completion Date :||February 28, 2008|
|Study Completion Date :||February 28, 2008|
Drug: inhaled human insulin
Treat-to-target dose titration scheme, inhalation.
|Active Comparator: B||
Drug: insulin aspart
Treat-to-target dose titration scheme, injection s.c.
- Changes in lung function, chest X-rays, or asthma exacerbation frequency [ Time Frame: after 52 weeks of treatment ]
- Diabetes control measured by change in HbA1c [ Time Frame: from baseline to end of treatment ]
- Laboratory assessments (biochemistry, insulin antibodies, blood count) [ Time Frame: from baseline to end of treatment ]
- Preprandial insulin doses [ Time Frame: for the duration of the trial ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00523042
Show 32 Study Locations
|Study Director:||Global Clinical Registry (GCR, 1452)||Novo Nordisk A/S|